PosterSessionOnline

INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA

12th International Conference on Malignant Lymphoma

19-22 June 2013 Lugano

N. Poster

Poster title

Applicant name

Status


161-P	BURKITTS LYMPHOMAS THAT ARISE SPONTANEOUSLY IN VKMYC MICE SHARE SIMILAR MUTATIONS WITH THE HUMAN DISEASE AND ARE ACCELERATED BY DIVERSE SURVIVAL SIGNALS.	marta chesi	Received

162-P	PRO-ONCOGENIC FUNCTIONS OF HSP105 IN HUMAN B-CELL NON-HODGKIN LYMPHOMAS	Massimo Di Nicola	Received

163-P	DIMERIZATION AND MONOUBIQUITINATION OF THE PARACASPASE MALT1 ARE REQUIRED FOR THE SURVIVAL OF CELLS DERIVED FROM ABC DLBCL	Margot Thome-Miazza	Received

166-P	EBV-SPECIFIC MICRO-RNA VIA EXOSOME: A KEY INTER-CELLULAR MACHINERY BETWEEN EBV TUMOR AND TUMOR-SURROUNDING IMMUNE CELLS?	Kotani Ai	Received

167-P	RICHTER SYNDROME (RS) PROMOTER METHYLATION DIFFERS FROM DE NOVO DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)	Afua Adjeiwaa Mensah	Received

168-P	THE GENOMIC LANDSCAPE OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)	Esteban Braggio	Received

169-P	QUANTITATIVE ULTRA DEEP SEQUENCING TO CHARACTERIZE CLONAL EVOLUTION OF FOLLICULAR LYMPHOMA	Richard Burack	Received

172-P	SELECTIVE QUANTIFICATION OF BMI-1 LEVELS IN THE NUCLEI OF FOLLICULAR LYMPHOMA CELLS SHOWS ITS ASSOCIATIONS WITH EZH2 GENE MUTATION AND REDUCED OVERALL SURVIVAL, INDEPENDENT OF FLIPI	Naif AlJohani	Received

173-P	MUM-1 IS A STRONG PROGNOSTIC IMMUNOHISTOCHEMICAL MARKER IN FOLLICULAR LYMPHOMA: COMPUTERIZED IMAGE ANALYSIS OF THE FL-2000 AND PRIMA RANDOMIZED GELA TRIALS.	Luc Xerri	Received

174-P	STRONG CD180 EXPRESSION : A NEW MARKER OF MARGINAL B-CELL LYMPHOMAS	Lucile BASEGGIO	Received

175-P	Multidimensional flow cytometry for sensitive evaluation of patients with IgM MGUS or Waldenstrms Macroglobulinemia and differential diagnosis with other lymphomas	Bruno Paiva	Received

176-P	CD70 T CELLS ARE INDICATIVE OF TGF--MEDIATED IMMUNE SUPPRESSION AND PREDICT A POOR OUTCOME IN FOLLICULAR LYMPHOMA PATIENTS	Zhizhang Yang	Received

178-P	OVEREXPRESSION OF MYC, BCL2, MYC/BCL2, IGM, AS WELL AS NON-GERMINAL CENTRE B-CELL LIKE IMMUNOPHENOTYPE PREDICT A WORSE PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL IN A SERIES OF 670 DE NOVO DIFFUSE LARGE B-CELL LYMPHOMAS: A LYSA STUDY.	Molina Thierry	Received

180-P	PROGNOSTIC SIGNIFICANCE AND PHENOTYPIC MANIFESTATIONS OF MYC/BCL2 PROTEIN CO-EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) WITH EXTRANODAL ORGAN INVOLVEMENT: A REPORT OF THE INTERNATIONAL DLBCL RITUXIMAB-CHOP CONSORTIUM PROGRAM STUDY	Anusha Madadi	Received

181-P	MICRORNAS OF THE MIR-17-92 CLUSTER PREDICT FOR OUTCOME IN R-CHOP-TREATED DIFFUSE LARGE B-CELL LYMPHOMA AND ARE SIGNIFICANTLY ASSOCIATED WITH EXPRESSION OF MYC PROTEIN	Rachel Culpin	Received

182-P	GENETIC ABNORMALITIES IN B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH FEATURES INTERMEDIATE BETWEEN DIFFUSE LARGE B-CELL LYMPHOMA AND BURKITT LYMPHOMA (B-UCL): THE NEBRASKA EXPERIENCE	ANAMARIJA PERRY	Received

186-P	PROGNOSTIC ROLE OF HISTOLOGICAL GRADE 3A IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA. RESULTS OF AN F2-STUDY DATABASE	Monica Bellei	Received

188-P	VIROLOGIC RESPONSE IMPROVES PROGNOSIS IN PATIENTS WITH HEPATITIS C ASSOCIATED B-CELL NON-HODGKIN LYMPHOMAS, NATIONAL ANRS HC-13 LYMPHO-C STUDY RESULTS.	Jean Marie Michot	Received

189-P	INFLUENCE OF LIFESTYLE FACTORS ON THE EXPRESSION OF TUMOR-RELATED MICROENVIRONMENT T-CELLS AND THE IMPACT ON SURVIVAL IN FOLLICULAR LYMPHOMA (FL)	Andrew Evens	Received

190-P	Comparison of CHOP v. CVP treatment in 837 United States Veterans with untreated follicular lymphoma	Kenneth R. Carson	Received

191-P	A MULTICENTER PHASE II TRIAL OF BORTEZOMIB (B) COMBINED WITH RITUXIMAB (R) THERAPY FOR UNTREATED HIGH TUMOR BURDEN (HTB) INDOLENT NON-HODGKIN LYMPHOMA (NHL)	Andrew Evens	Received

192-P	FLUDARABINE-MITOXANTRONE-RITUXIMAB REGIMEN IN UNTREATED INTERMEDIATE/HIGH-RISK FOLLICULAR NON-HODGKIN	Pier Luigi Zinzani	Received

194-P	PHARMACOKINETICS (PK), SAFETY, AND OVERALL RESPONSE RATE (ORR) ACHIEVED WITH SUBCUTANEOUS (SC) RITUXIMAB (R) PLUS CHEMOTHERAPY (CT) WERE COMPARABLE TO THOSE WITH INTRAVENOUS (IV) ADMINISTRATION IN THE 1LTREATMENT OF PATIENTS (PTS) WITH FL	Chelsy Viereck	Received

196-P	FCGR3A AND FCGR2A POLYMORPHISMS DO NOT PREDICT RESPONSE RATE OR DURATION IN FOLLICULAR LYMPHOMA PATIENTS TREATED WITH SINGLE-AGENT RITUXIMAB: A PROSPECTIVE CORRELATIVE ANALYSIS FROM THE RESORT STUDY (ECOG E4402).	Brad Kahl	Received

199-P	THE USE OF RITUXIMAB AT FIRST-LINE DOES NOT IMPAIR THE EFFICACY OF SECOND-LINE THERAPY IN PATIENTS WITH FOLLICULAR LYMPHOMA. RESULTS OF THE REFOLL STUDY BY THE FONDAZIONE ITALIANA LINFOMI (FIL).	Giuseppe Rossi	Received

201-P	TREATMENT OF FOLLICULAR LYMPHOMA WITH RADIOIMMUNOTHERAPY DATA FROM THE RADIOIMMUNOTHERAPY NETWORK, AN INTERNATIONAL DATA BASE ON DAILY CLINICAL PRACTICE	Christian Scholz	Received

203-P	A POINT SCORE SIMPLIFICATION FOR PRACTICAL USE OF THE RISK STRATIFICATION FOR SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) BASED ON HEMOGLOBIN, PLATELET COUNT, HIGH LDH LEVEL AND EXTRAHILAR LYMPHADENOPATHY.	Carlos Montalban	Received

204-P	PERFORMANCE OF THE MONOCLONAL ASSAY FOR CIRCULATING FREE LIGHT CHAINS (FLC) IN AL AMYLOIDOSIS	Giovanni Palladini	Received

205-P	B-CELL NON-HODGKIN LYMPHOMA (B-NHL) AMONG ISRAELIS AND PALESTINIANS: DIVERSE DISEASE PATTERNS AND RISK FACTORS IN POPULATIONS IN GEOGRAPHIC PROXIMITY	Ora Paltiel	Received

206-P	EFFECT OF PLACE OF RESIDENCE AND CARE ON SURVIVAL OUTCOMES IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA	Diego Villa	Received

207-P	AN ENHANCED INTERNATIONAL PROGNOSTIC INDEX (NCCN-IPI) FOR RISK STRATIFICATION OF DLBCL PATIENTS IN THE RITUXIMAB ERA: VALIDATION USING THE BRITISH COLUMBIA CANCER AGENCY (BCCA) DATABASE	Zheng Zhou	Received

208-P	IMPACT OF GENDER, BODY MASS INDEX (BMI) AND BODY SURFACE AREA (BSA) ON OUTCOMES OF DLBCL PATIENTS TREATED WITH RITUXIMAB (R): ANALYSIS OF THE U.S. NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) DATABASE	Zheng Zhou	Received

212-P	R-CHOEP-14 IMPROVES OVERALL SURVIVAL IN YOUNG HIGH-RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA COMPARED WITH R-CHOP-14. AN UPDATED ANALYSIS WITH 5 YEARS MEDIAN FOLLOW UP OF THE POPULATION-BASED INVESTIGATION FROM THE DANISH LYMPHOMA GROUP.	Anne Ortved Gang	Received

214-P	PHASE 2 STUDY OF RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE WITH BORTEZOMIB (VCR-CAP) OR VINCRISTINE (R-CHOP) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED NON-GERMINAL CENTER B-CELL-LIKE (GCB) DLBCL	Fritz Offner	Received

215-P	RESULTS OF A PHASE 2 MULTICENTER STUDY OF THE ADDITION OF RITUXIMAB (R) TO CODOX-M/IVAC FOR UNTREATED BURKITTS LYMPHOMA (BL): IMPACT OF PLASMA AND CEREBROSPINAL FLUID (CSF) R LEVELS	Andrew Evens	Received

216-P	TUMOR EPSTEIN-BARR VIRUS (EBV) REPLICATION IS ASSOCIATED WITH EARLY-ONSET AND AGGRESSIVE BEHAVIOR OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD)	Jordina Rovira Solé	Received

217-P	EPSTEIN BARR VIRUS (EBV) PRIMO-INFECTIONS (PI) AND REACTIVATION (REA) TREATMENT AFTER HEART TRANSPLANTATION, IN PREVENTION OF POST-TRANSPLANTATION LYMPHOPROLIFERATION DISEASE (PTLD).	Sylvain Choquet	Received

218-P	RISK-TAILORED CNS PROPHYLAXIS IN A MONOINSTITUTIONAL SERIES OF 194 PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED IN THE RITUXIMAB ERA	Andrés Ferreri	Received

220-P	INFLUENCE OF PRIOR RITUXIMAB ON THE RESULTS OF AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA: A GELTAMO STUDY.	ALBA MARÍA REDONDO	Received

221-P	COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) IS AN ESSENTIAL TOOL TO SUPPORT TREATMENT DECISIONS IN ELDERLY PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL). RESULTS OF A MULTICENTER STUDY BY THE FONDAZIONE ITALIANA LINFOMI (FIL)	Alessandra Tucci	Received

222-P	ELDERLY IPI (EIPI) IN DLBCL PTS AGE 60 Y TREATED WITH RCHOP: INTERNATIONAL VALIDATION STUDY USING DATA FROM RICOVER-60 (GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP) AND LNH 98-5 (GROUPE DETUDE DE LYMPHOME DADULTES)	Ranjana Advani	Received

224-P	TREATMENT APPROACH AND CAUSE SPECIFIC SURVIVAL IN ELDERLY PATIENTS DIAGNOSED WITH DIFFUSE LARGE B-CELL LYMPHOMA.	Anna Dyszkiewicz-Korpanty	Received

225-P	PATIENT-REPORTED SYMPTOMS ARE STILL THE SINGLE MOST IMPORTANT FACTOR FOR DETECTING LYMPHOMA RELAPSE	Tarec Christoffer El-Galaly	Received

227-P	IMMUNOGENETIC ANALYSIS OF THE B-CELL REPERTOIRE OF INDOLENT MCL WITH A SPLENIC PRESENTATION	clémentine sarkozy	Received

230-P	PREEMPTIVE IMMUNOTHERAPY WITH RITUXIMAB SIGNIFICANTLY PROLONGS THE DISEASE-FREE SURVIVAL IN PATIENTS WITH MOLECULAR RELAPSE OF MANTLE CELL LYMPHOMA	David Salek	Received

235-P	LONG-TERM FOLLOW-UP OF THE PHASE II STUDY OF SMILE CHEMOTHERAPY FOR PATIENTS WITH NEWLY-DIAGNOSED STAGE IV, RELAPSED OR REFRACTORY EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE: THE NK-CELL TUMOR STUDY GROUP (NKTSG) STUDY	Ritsuro Suzuki	Received

239-P	MANAGEMENT AND PROGNOSIS OF PATHOLOGICAL FRACTURES (PF) IN A SERIES OF 373 PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF THE BONE (THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP IELSG 14 STUDY)	Silvia Govi	Received

241-P	HIGH DOSE THERAPY WITH AUTOLOGOUS STEM CELL SUPPORT FOR PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS FROM THE ADULT LYMPHOMA WORKING GROUP OF THE JAPAN SOCIETY FOR HEMATOPOIETIC CELL TRANSPLANTATION (JSHCT)	Eisei Kondo	Received

242-P	INTENSIVE THERAPY OF THE PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA	Elena Baryakh	Received

243-P	CLINICAL FEATURES AND TREATMENT OUTCOMES OF PATIENTS WITH EXTRANODAL NK/T-CELL LYMPHOMA IN GASTROINTESTINAL TRACT: RESULTS OF MULTICENTER RETROSPECTIVE ANALYSIS	Won Seog Kim	Received

244-P	Non-coding RNAs in cerebrospinal fluid as biomarker for primary central nervous system lymphoma	Alexander Baraniskin	Received

246-P	SIMILAR CHEMOKINE RECEPTOR PROFILES IN PCNSL AND SECONDARY CNS INVOLVEMENT OF SYSTEMIC DLBCL	Anna Kaisa Pasanen	Received

247-P	RITUXIMAB IN COMBINATION WITH METHOTREXATE-BASED CHEMOTHERAPY WITH BLOOD-BRAIN BARRIER DISRUPTION IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA	Nancy Doolittle	Received

249-P	PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL): A RETROSPECTIVE ANALYSIS OF DATA FROM THE DANISH LYMPHOMA REGISTRY LYFO	Danny Stoltenberg	Received

250-P	IELSG 34 FINAL RESULTS OF A MULTICENTER PHASE II STUDY TO EVALUATE THE CLINICAL ACTIVITY AND THE SAFETY OF EVEROLIMUS IN MARGINAL ZONE B-CELL LYMPHOMAS (MZL)	Annarita Conconi	Received

253-P	RISK FACTORS AND STAGING SYSTEMS IN EARLY STAGE HODGKIN LYMPHOMA PATIENTS HAVE SIGNIFICANT IMPACT ON TREATMENT OUTCOME AFTER MODERN COMBINED MODALITY TREATMENT.	Beate Klimm	Received

254-P	DEEP INSPIRATION BREATH HOLD RADIATION THERAPY REDUCES RADIATION DOSE TO HEART IN PATIENTS TREATED FOR MEDIASTINAL HODGKIN LYMPHOMA	Peter Meidahl Petersen	Received

255-P	TAILORING THERAPY IN HODGKIN LYMPHOMA BASED ON PREDEFINED RISK FACTORS AND EARLY INTERIM PET/CT: ISRAELI H2 STUDY -PRELIMINARY REPORT ON 306 PATIENTS	Eldad J Dann	Received

256-P	PATTERNS OF FAILURE (POF) IN A RANDOMIZED PHASE III TRIAL OF ABVD VS. STANFORD V /- RADIATION THERAPY (RT) IN LOCALLY EXTENSIVE AND ADVANCED STAGE HODGKINS LYMPHOMA (HL): AN INTERGROUP STUDY COORDINATED BY THE EASTERN COOPERATIVE ONCOLOGY GROUP (E2496)	Henry Wagner	Received

257-P	PHARMACOGENETIC ANALYSIS OF CYP2B6 IN THE LRF CLL4 TRIAL: THE 6 ALLELIC VARIANT IS ASSOCIATED WITH INFERIOR EFFICACY FOLLOWING FLUDARABINE PLUS CYCLOPHOSPHAMIDE	Gillian Johnson	Received

258-P	THE PROGNOSTIC IMPACT OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA REQUIRING FIRST-LINE THERAPY	Julio Delgado	Received

259-P	A HIGH NUMBER OF LOSSES IN 11Q CHROMOSOME IS ASSOCIATED WITH SHORT TIME TO FIRST TREATMENT AND OVERALL SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. FINAL RESULTS OF DATABASE OF CLL OF SPANISH GROUP OF CYTOGENETICS AND SPANISH GROUP OF CLL	JOSE-ANGEL HERNANDEZ	Received

260-P	FLUDARABINE, RITUXIMAB, AND LENALIDOMIDE IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	Ian Flinn	Received

261-P	PLATINUM AND HIGH-DOSE CYTARABINE-BASED REGIMENS ARE EFFICIENT IN ULTRA HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA : RESULTS OF A RETROSPECTIVE MULTICENTER STUDY	Eric DUROT	Received

262-P	CYTOKINE QUANTIFICATION IN HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS TREATED WITH IBRUTINIB AND RITUXIMAB	Iris de Weerdt	Received

264-P	THE EFFECT OF MOLECULAR SUBCLASS ON PATIENT OUTCOMES AFTER RADIOIMMUNOTHERAPY-BASED CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA	Tanya Siddiqi	Received

265-P	TREATMENT OF PERIPHERAL T-CELL LYMPHOMA WITH AGGRESSIVE INDUCTION CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT USING DENILEUKIN DIFTITOX (DD) FOR IN VIVO PURGING AND POST-TRANSPLANT THERAPY: PRELIMINARY RESULTS OF A PHASE II CLINICAL TRIAL	Lawrence Kaplan	Received

266-P	AUTOLOGOUS AND ALLOGENEIC STEM-CELL TRANSPLANTATION FOR TRANSFORMED NON-FOLLICULAR INDOLENT LYMPHOMA: A REPORT OF THE CANADIAN BLOOD AND MARROW TRANSPLANT GROUP	Diego Villa	Received

270-P	BASELINE METABOLIC TUMOR VOLUME PREDICTS PATIENTS OUTCOME IN HODGKIN LYMPHOMA	cédric rossi	Received

271-P	FDG PET-CT AFTER FIRST-LINE TREATMENT PREDICTS PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL)	Eukene Gainza	Received

272-P	PROGNOSTIC VALUE OF 18FDG BASELINE FUNCTIONAL PET PARAMETERS IN PRIMARY MEDIASTINAL DIFFUSE LARGE B-CELL LYMPHOMA (PMLBCL)	Luca Ceriani	Received

273-P	18F-FLUORODEOXYGLUCOSE (FDG) OUTPERFORMS 18F-FLUOROTHYMIDINE (FLT) IN IDENTIFYING TRANSFORMATION OF FOLLICULAR LYMPHOMA, IN PARTICULAR THROUGH HETEROGENEITY IN UPTAKE	Marielle Wondergem	Received

274-P	INTERIM PET SUVMAX REDUCTION IS SUPERIOR TO VISUAL ANALYSIS TO PREDICT PATIENTS OUTCOME IN HODGKIN LYMPHOMA	Cédric rossi	Received

276-P	COMPARATIVE ASSESSMENT OF BONE MARROW INVOLVEMENT (BMI) BY BM BIOPSY (BMB) OR POSITRON EMISSION TOMOGRAPHY (PET) IN HODGKIN LYMPHOMA (HL)	Theodoros Vassilakopoulos	Received

277-P	A NOVEL ORAL BRUTONS TYROSINE KINASE (BTK) INHIBITOR THAT DEMONSTRATES POTENT PHARMACODYNAMIC ACTIVITY THROUGH PHOSPHORYLATED BTK (P-BTK) INHIBITION, IN ADDITION TO EFFECTIVE ANTI-TUMOUR ACTIVITY IN A DLBCL XENOGRAFT MODEL)	Toshio Yoshizawa	Received

278-P	GENOMIC INSTABILITY AND ACTIVATION OF THE DNA DAMAGE RESPONSE PATHWAY IS AN INDEPENDENT PREDICTOR OF POOR PROGNOSIS AND A PROMISING TARGET FOR THERAPY IN DIFFUSE LARGE B CELL LYMPHOMA	Enrico Derenzini	Received

279-P	TARGETING SIGNALING PATHWAYS IN MYCOSIS FUNGOIDES AND SEZARY SYNDROME	Wei Ai	Received

281-P	A NEW THERAPEUTIC APPROACH FOR THE THERAPY OF B-CELL DISORDERS: DRUG-LOADED ANTI-CD20 NANOPARTICLES)	Gabriele Pozzato	Received

284-P	DARATUMUMAB, A NOVEL HUMAN CD38 MONOCLONAL ANTIBODY FOR THE TREATMENT OF B-CELL NONHODGKIN LYMPHOMA	Patricia Pérez-Galán	Received

285-P	EFFECTS OF RITUXIMAB AND GA-101 ON IN VITRO KILLING OF CELL LINES AND PATIENT LYMPHOMA CELLS BY NORMAL DONOR OR PATIENT EFFECTOR CELLS	Huei Shan Wu	Received

289-P	BENDAMUSTINE, LENALIDOMIDE, AND RITUXIMAB IN RELAPSED AND REFRACTORY LYMPHOID MALIGNANCIES	Bruce Cheson	Received

292-P	EFFICACY AND SAFETY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB (IR) IN HIGH-RISK CLL PATIENTS	Jan A. Burger	Received

299-P	PHASE II MULTICENTER STUDY OF LENALIDOMIDE IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA POST-BORTEZOMIB: MCL-001 EMERGE STUDY	marybeth McKenzie	Received

306-P	ARE MONOCLONAL ANTIBODIES NECESSARY IN THE TREATMENT OF CHILDRENS B-NON HODGKIN LYMPHOMA?	Josip Konja	Received

308-P	OUTCOME AND TOXICITY PATTERNS IN CHILDREN WITH NON-HODGKINS LYMPHOMA	Oussama Abla	Received

309-P	MANAGEMENT OF PEDIATRIC HODGKIN LYMPHOMA IN CROATIA	Josip Konja	Received

310-P	RAPID EARLY RESPONSE TO HIGH-DOSE METHOTREXATE IN AN ADOLESCENT WITH MULTIFOCAL PRIMARY CNS LYMPHOMA	Oussama Abla	Received

12th International Conference on Malignant Lymphoma

19-22 June 2013 Lugano

About us

CLICK HERE TO SEE A PRESENTATION OF THE NEW-LOOK POSTERSESSIONONLINE VIEWER.

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 19/04/2013 TO 22/06/2018

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum

DOI: 10.3252/pso.eu.12icml.2013



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access